跳至主要内容
临床试验/NCT07289750
NCT07289750尚未招募4 期

The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-associated Fatty Liver Disease

The Fourth Affiliated Hospital of Zhejiang University School of Medicine0 个研究点目标入组 80 人开始时间: 2026年5月1日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
80
主要终点
hemoglobin A1c

研究概览

简要总结

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of T2DM
  • Clinical diagnosis of MAFLD
  • HbA1c: 6.5-9.5%
  • BMI: 19-35 kg/m2
  • No hypoglycemic drugs or insulin have been used within half a year

排除标准

  • Severe infections, surgeries and other emergency
  • Other types of diabetes
  • Severe cardiovascular, brain, liver and kidney disorders
  • Malignant tumor

结局指标

主要结局

hemoglobin A1c

时间窗: 6 months of treatment

次要结局

未报告次要终点

研究者

发起方
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
申办方类型
Other
责任方
Sponsor

相似试验